Cargando…
In Vivo Targeting of Escherichia coli with Vancomycin-Arginine
The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to Gram-negative bacteria was investigated. Its MIC towards Escherichia coli, including β-lactamase expressing Ambler classes A, B, and D, was 8 to 16 μg/ml. Addition of 8 times the MIC of V-r to E. coli was...
Autores principales: | Neville, Lewis F., Shalit, Itamar, Warn, Peter A., Scheetz, Marc H., Sun, Jiuzhi, Chosy, Madeline B., Wender, Paul A., Cegelski, Lynette, Rendell, Jacob T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097466/ https://www.ncbi.nlm.nih.gov/pubmed/33468474 http://dx.doi.org/10.1128/AAC.02416-20 |
Ejemplares similares
-
Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model
por: Neville, Lewis F., et al.
Publicado: (2022) -
Unraveling Escherichia coli’s Cloak: Identification of Phosphoethanolamine Cellulose, Its Functions, and Applications
por: Jeffries, Jamie, et al.
Publicado: (2019) -
The Congo red derivative FSB binds to curli amyloid fibers and specifically stains curliated E. coli
por: Reichhardt, Courtney, et al.
Publicado: (2018) -
Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures
por: Philip, R, et al.
Publicado: (2003) -
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)